International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.7947306
Original Article
Comparative Study of Intracervical Dinoprostone Gel Versusvaginal Misoprostol for Cervical Ripening and Induction of Labour
 ,
 ,
Published
May 18, 2023
Abstract
Background and objective: The induction of labour is nonspontaneous initiation of uterine contractions before their spontaneous onset leading to progressive effacement and dilatation of cervix and delivery of the baby. Overall rate of induction of labour has increased over last decade. PGE2 has been used for more than a decade for cervical ripening and induction of labour. its been evidenced in literature that misoprostol a PGE1 analogue is extensively evaluated for cervical ripening and induction of labour. We aim to compare between the efficacy of intracervical dinoprostone gel versus vaginal misoprostol tablets for the cervical ripening and induction of labour. Method: This was a prospective study. 100 women which were admitted and who fulfilled the criteria, 100 cases were randomized equally in two groups, 50 patients underwent induction with dinoprostone gel 0.5mg intracevically every 6 hourly till maximum 3 doses and in another group of 50 pts , labour was induced by 25 mcg of misoprostol in posterior fornix of vagina every 4 hourly for maximum 5 doses. Result: In 72% pts in misoprostol group the Bishop score was 2-3,in 90% of pts 25-75mcg of misoprostol was required for successful induction of labour when compared to 66% of cases in dinoprostone group by single application. Induction delivery interval was between 5-18 hours in 84% of cases in the misoprostol group , whereas in only 68% cases , in dinoprostone group induction delivery interval was 7-18 hours . Incidence of LSCS was also less around 6% In misoprostol group when compared to 16% in dinoprostonegroup, cost of misoprostol is cheaper 70/- when compared to 250/-in dinoprostone group. Meconium staining of liquor was found to 8% with misoprostol and 4% in with dinoprostone group.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
81 Views
272 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved